It does not take much to elicit criticism from Center for Drug Evaluation & Research Deputy Director Bob Temple on observational and meta-analysis studies as serious regulatory tools.
At a recent Institute of Medicine meeting on “Characterizing and Communicating Uncertainty” in FDA’s benefit/risk decisions, Temple described the reluctance to consider sources of information beyond randomized